首页> 美国卫生研究院文献>other >Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation Inflammation and Angiogenesis in Chronic Allograft Nephropathy
【2h】

Long-Term Gene Therapy with Thrombospondin 2 Inhibits TGF-β Activation Inflammation and Angiogenesis in Chronic Allograft Nephropathy

机译:血小板反应蛋白2的长期基因治疗抑制慢性异体移植肾病中的TGF-β活化炎症和血管生成。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature.
机译:我们最近通过使用TSP-2空小鼠将Thrombospondin-2(TSP-2)鉴定为实验性肾脏疾病中基质重塑和炎症的调节剂,并成功证明TSP-2过表达是大鼠短期肾小球肾炎模型中的一种治疗概念。 。在本研究中,我们研究了长期TSP-2过表达是否还能够改善大鼠慢性同种异体移植肾病F344-Lewis模型中慢性肾脏疾病的进展。肾移植后两周,仅用过表达TSP-2的质粒(n = 8)或以荧光素酶表达的质粒(n = 8)转染两只大鼠大腿肌肉一次。监测大鼠移植后长达30周的肾功能,组织学变化和基因表达。出乎意料的是,与荧光素酶治疗的对照组相比,仅在TSP-2治疗组中有2只大鼠在实验结束前死亡,并且TSP-2组的肾功能趋于恶化。此外,尽管TGF-β活化降低且在此过程中具有显着的抗炎作用(巨噬细胞,T细胞和B细胞),但TSP-2治疗的肾脏中肾小球硬化和肾小管间质损伤以及皮质纤连蛋白沉积显着增加。组。与对照组相比,TSP-2治疗大鼠的移植肾中长期肾小球和肾小管内皮稀疏性明显升高,内皮细胞增殖减少,这证明长期TSP-2治疗损害了肾内皮的修复。 TSP-2的作用与肾VEGF的水平降低有关,而与VEGF1受体的降低无关。总之,尽管具有抗炎和TGF-β激活阻断作用,TSP-2基因治疗并没有改善,反而恶化了实验性慢性同种异体移植肾病,这很可能是由于其对肾脏微血管的抗血管生成特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号